Ellen Meier1, Ryan Vandrey2, Nathan Rubin3, Lauren R Pacek4, Joni A Jensen5, Eric C Donny6, Stephen S Hecht3, Steven G Carmella3, Sharon E Murphy3, Xianghua Luo3,7, Irina Stepanov4,6, Joshua Ikuemonisan3, Herb Severson8, Mustafa al'Absi9, Dorothy K Hatsukami5. 1. University of Wisconsin - Stevens Point, Stevens Point, WI. 2. Johns Hopkins University School of Medicine, Baltimore, MD. 3. University of Minnesota Masonic Cancer Center, Minneapolis, MN. 4. Department of Psychiatry, Duke University School of Medicine, Durham, NC. 5. University of Minnesota, Tobacco Research Programs, Minneapolis, MN. 6. Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC. 7. Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN. 8. Oregon Research Institute. 9. University of Minnesota Medical School, Duluth, MN.
Abstract
INTRODUCTION: Cannabis and tobacco co-use is common and could exposure users to higher levels of toxicants. No studies have examined biomarkers of toxicant exposure in co-users of cannabis and cigarettes, compared with cigarette smokers. METHODS: Adult daily cigarette smokers were recruited from 10 U.S. sites for a study of reduced nicotine cigarettes. In this analysis of baseline data, participants were categorized as either co-users of cannabis and tobacco (co-users; N=167; urine positive for 11-nor-9-carboxy-Δ9-tetrahydrocannnabinol and self-reported cannabis use ≥1x/week), or cigarette smokers (CS; N=911; negative urine and no self-reported cannabis use). Participants who did not meet either definition (N=172) were excluded. Self-reported tobacco and cannabis use and tobacco/combustion-related biomarkers of exposure were compared between groups. RESULTS: Compared to CS, co-users were younger (co-user Mage=38.96, SD=13.01; CS Mage=47.22, SD=12.72; p<.001) and more likely to be male (co-users=67.7%, CS=51.9%, p<.001). There were no group differences in self-reported cigarettes/day, total nicotine equivalents, or breath carbon monoxide, but co-users had greater use of non-cigarette tobacco products. Compared to CS, co-users had higher concentrations of 3-hydroxypropylmercapturic acid, 2-cyanoethylmercapturic acid, S-phenylmercapturic acid, 3-hydroxy-1-methylpropylmercapturic acid (ps<.05) and phenanthrene tetraol (PheT; p<.001). No biomarkers were affected by number of cannabis use days/week or days since last cannabis use during baseline (p's > .05). CONCLUSIONS: Co-users had higher concentrations of biomarkers of exposure than CS, but similar number of cigarettes per day and nicotine exposure. Additional studies are needed to determine whether cannabis and/or alternative tobacco products are driving the increased toxicant exposure. IMPLICATIONS: Co-users of cannabis and tobacco appear to be exposed to greater levels of harmful chemicals (i.e., volatile organic compounds and polycyclic aromatic hydrocarbons), but similar levels of nicotine as cigarette smokers. It is unclear if the higher levels of toxicant exposure in co-users are due to cannabis use or the increased use of alternative tobacco products compared with cigarette smokers. It is important for studies examining biomarkers of exposure among cigarette smokers to account for cannabis use as it may have a significant impact on outcomes. Additionally, further research is needed examining exposure to harmful chemicals among cannabis users.
INTRODUCTION: Cannabis and tobaccoco-use is common and could exposure users to higher levels of toxicants. No studies have examined biomarkers of toxicant exposure in co-users of cannabis and cigarettes, compared with cigarette smokers. METHODS: Adult daily cigarette smokers were recruited from 10 U.S. sites for a study of reduced nicotine cigarettes. In this analysis of baseline data, participants were categorized as either co-users of cannabis and tobacco (co-users; N=167; urine positive for 11-nor-9-carboxy-Δ9-tetrahydrocannnabinol and self-reported cannabis use ≥1x/week), or cigarette smokers (CS; N=911; negative urine and no self-reported cannabis use). Participants who did not meet either definition (N=172) were excluded. Self-reported tobacco and cannabis use and tobacco/combustion-related biomarkers of exposure were compared between groups. RESULTS: Compared to CS, co-users were younger (co-user Mage=38.96, SD=13.01; CS Mage=47.22, SD=12.72; p<.001) and more likely to be male (co-users=67.7%, CS=51.9%, p<.001). There were no group differences in self-reported cigarettes/day, total nicotine equivalents, or breath carbon monoxide, but co-users had greater use of non-cigarette tobacco products. Compared to CS, co-users had higher concentrations of 3-hydroxypropylmercapturic acid, 2-cyanoethylmercapturic acid, S-phenylmercapturic acid, 3-hydroxy-1-methylpropylmercapturic acid (ps<.05) and phenanthrene tetraol (PheT; p<.001). No biomarkers were affected by number of cannabis use days/week or days since last cannabis use during baseline (p's > .05). CONCLUSIONS:Co-users had higher concentrations of biomarkers of exposure than CS, but similar number of cigarettes per day and nicotine exposure. Additional studies are needed to determine whether cannabis and/or alternative tobacco products are driving the increased toxicant exposure. IMPLICATIONS: Co-users of cannabis and tobacco appear to be exposed to greater levels of harmful chemicals (i.e., volatile organic compounds and polycyclic aromatic hydrocarbons), but similar levels of nicotine as cigarette smokers. It is unclear if the higher levels of toxicant exposure in co-users are due to cannabis use or the increased use of alternative tobacco products compared with cigarette smokers. It is important for studies examining biomarkers of exposure among cigarette smokers to account for cannabis use as it may have a significant impact on outcomes. Additionally, further research is needed examining exposure to harmful chemicals among cannabis users.
Authors: Shannon Gravely; Pete Driezen; Danielle M Smith; Ron Borland; Eric N Lindblom; David Hammond; Ann McNeill; Andrew Hyland; K Michael Cummings; Gary Chan; Mary E Thompson; Christian Boudreau; Nadia Martin; Janine Ouimet; Ruth Loewen; Anne C K Quah; Maciej L Goniewicz; James F Thrasher; Geoffrey T Fong Journal: Int J Drug Policy Date: 2020-04-16
Authors: Mustafa al'Absi; Briana DeAngelis; Mark Fiecas; Alan Budney; Sharon Allen Journal: Psychopharmacology (Berl) Date: 2022-03-11 Impact factor: 4.415
Authors: David R Lorenz; Vikas Misra; Sukrutha Chettimada; Hajime Uno; Lanqing Wang; Benjamin C Blount; Víctor R De Jesús; Benjamin B Gelman; Susan Morgello; Steven M Wolinsky; Dana Gabuzda Journal: EClinicalMedicine Date: 2021-01-11
Authors: Ellen Meier; Katelyn M Tessier; Xianghua Luo; Laura Dick; Nicole M Thomson; Stephen S Hecht; Steven G Carmella; Sharon Murphy; Dorothy K Hatsukami Journal: Nicotine Tob Res Date: 2022-01-01 Impact factor: 5.825